Insulin induces heterologous desensitization of G-protein-coupled receptor and insulin-like growth factor I signaling by downregulating beta-arrestin-1

Mol Cell Biol. 2002 Sep;22(17):6272-85. doi: 10.1128/MCB.22.17.6272-6285.2002.

Abstract

beta-Arrestin-1 mediates agonist-dependent desensitization and internalization of G protein-coupled receptors (GPCRs) and is also essential for GPCR mitogenic signaling. In addition, insulin-like growth factor I receptor (IGF-IR) endocytosis is facilitated by beta-arrestin-1, and internalization is necessary for IGF-I-stimulated mitogen-activated protein (MAP) kinase activation. Here, we report that treatment of cells for 12 h with insulin (100 ng/ml) induces an approximately 50% decrease in cellular beta-arrestin-1 content due to ubiquitination of beta-arrestin-1 and proteosome-mediated degradation. This insulin-induced decrease in beta-arrestin-1 content was blocked by inhibition of phosphatidylinositol-3 kinase (PI-3 kinase) and MEK with wortmannin and PD98059, respectively. We also found a marked decrease in the association of beta-arrestin-1 with the IGF-IR and a 55% inhibition of IGF-I-stimulated MAP kinase phosphorylation. In insulin-treated, beta-arrestin-1-downregulated cells, there was complete inhibition of lysophosphatidic acid (LPA) or isoproterenol (ISO)-stimulated MAP kinase phosphorylation. This was associated with a decrease in beta-arrestin-1 association with the beta2-AR as well as a decrease in beta-arrestin-1-Src and Src-beta2-AR association. Ectopic expression of wild-type beta-arrestin-1 in insulin-treated cells in which endogenous beta-arrestin-1 had been downregulated rescued IGF-I- and LPA-stimulated MAP kinase phosphorylation. In conclusion, we found the following. (i) Chronic insulin treatment leads to enhanced beta-arrestin-1 degradation. (ii) This downregulation of endogenous beta-arrestin-1 is associated with decreased IGF-I-, LPA-, and ISO-mediated MAP kinase signaling, which can be rescued by ectopic expression of wild-type beta-arrestin-1. (iii) Finally, these results describe a novel mechanism for heterologous desensitization, whereby insulin treatment can impair GPCR signaling, and highlight the importance of beta-arrestin-1 as a target molecule for this desensitization mechanism.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3T3 Cells / drug effects
  • Adipocytes / drug effects
  • Adrenergic beta-Agonists / pharmacology
  • Animals
  • Arrestins / metabolism*
  • Enzyme Inhibitors / pharmacology
  • Epidermal Growth Factor / pharmacology
  • GTP-Binding Proteins / physiology*
  • Humans
  • Insulin / pharmacology*
  • Insulin-Like Growth Factor I / pharmacology*
  • Isoproterenol / pharmacology
  • Lysophospholipids / pharmacology
  • MAP Kinase Kinase 1
  • MAP Kinase Signaling System / drug effects
  • Mice
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
  • Peptide Hydrolases / metabolism
  • Phosphatidylinositol 3-Kinases / physiology
  • Phosphoinositide-3 Kinase Inhibitors
  • Proteasome Endopeptidase Complex*
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Proto-Oncogene Proteins pp60(c-src) / metabolism
  • Rats
  • Receptor, IGF Type 1 / metabolism
  • Receptor, Insulin / drug effects
  • Receptor, Insulin / physiology
  • Receptors, Adrenergic, beta-2 / drug effects*
  • Receptors, Adrenergic, beta-2 / physiology
  • Recombinant Fusion Proteins / drug effects
  • Recombinant Fusion Proteins / physiology
  • Signal Transduction / drug effects*
  • Signal Transduction / physiology
  • Ubiquitin / metabolism
  • beta-Arrestin 1
  • beta-Arrestins

Substances

  • ARRB1 protein, human
  • Adrenergic beta-Agonists
  • Arrb1 protein, mouse
  • Arrb1 protein, rat
  • Arrestins
  • Enzyme Inhibitors
  • Insulin
  • Lysophospholipids
  • Phosphoinositide-3 Kinase Inhibitors
  • Receptors, Adrenergic, beta-2
  • Recombinant Fusion Proteins
  • Ubiquitin
  • beta-Arrestin 1
  • beta-Arrestins
  • Epidermal Growth Factor
  • Insulin-Like Growth Factor I
  • Receptor, IGF Type 1
  • Receptor, Insulin
  • Proto-Oncogene Proteins pp60(c-src)
  • Protein Serine-Threonine Kinases
  • MAP Kinase Kinase 1
  • MAP2K1 protein, human
  • Map2k1 protein, mouse
  • Mitogen-Activated Protein Kinase Kinases
  • Peptide Hydrolases
  • Proteasome Endopeptidase Complex
  • ATP dependent 26S protease
  • GTP-Binding Proteins
  • Isoproterenol